Option chain shows key data for Iris Acquisition's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Iris Acquisition.

Iris Acquisition (OTC:IRAAU) Stock, Option Chain

Iris Acquisition Corp is a blank check company.

Iris Acquisition Corp Units (1 Ord Share Class A & 1/4 War)

Iris Acquisition Corp

<p>Deep-pocketed investors have adopted a bearish approach towards Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Alcoa. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $77,695, and 8 are calls, amounting to $1,210,239.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $50.0 for Alcoa during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Alcoa stands at 5407.0, with a total volume reaching 3,174.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Alcoa, situated within the strike price corridor from $25.0 to $50.0, throughout the last 30 days.</p>
<h3>Alcoa Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732646826_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$22.3</td>
<td>$22.2</td>
<td>$22.25</td>
<td>$25.00</td>
<td>$852.0K</td>
<td>658</td>
<td align="right">0</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.3</td>
<td>$6.15</td>
<td>$6.3</td>
<td>$50.00</td>
<td>$63.0K</td>
<td>86</td>
<td align="right">400</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.2</td>
<td>$5.95</td>
<td>$6.2</td>
<td>$50.00</td>
<td>$62.0K</td>
<td>86</td>
<td align="right">200</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$6.25</td>
<td>$6.05</td>
<td>$6.2</td>
<td>$50.00</td>
<td>$62.0K</td>
<td>86</td>
<td align="right">100</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.2</td>
<td>$2.19</td>
<td>$2.19</td>
<td>$50.00</td>
<td>$61.5K</td>
<td>16.3K</td>
<td align="right">510</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alcoa</h3>
<p>Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is the world's largest bauxite miner and alumina refiner by production volume, and the eighth-largest aluminum producer. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024, meaning refining assets are now predominantly wholly owned, as with smelting.</p>
<p>Following our analysis of the options activities associated with Alcoa, we pivot to a closer look at the company's own performance.</p>
<h3>Alcoa's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,858,883, the AA's price is down by -0.31%, now at $47.07. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 50 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alcoa with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Spotlight on Alcoa: Analyzing the Surge in Options Activity

<p>Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 25% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $307,864, and 2 were calls, valued at $62,250.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $185.0 for Biogen during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Biogen options trades today is 215.75 with a total volume of 4,319.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $100.0 to $185.0 over the last 30 days.</p>
<h3>Biogen Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732646821_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$28.4</td>
<td>$22.7</td>
<td>$27.2</td>
<td>$185.00</td>
<td>$35.3K</td>
<td align="right">443</td>
<td align="right">13</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.7</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$160.00</td>
<td>$34.3K</td>
<td align="right">335</td>
<td align="right">99</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$15.6</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$160.00</td>
<td>$34.1K</td>
<td align="right">335</td>
<td align="right">422</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$11.5</td>
<td>$11.4</td>
<td>$11.5</td>
<td>$170.00</td>
<td>$33.3K</td>
<td align="right">83</td>
<td align="right">52</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.7</td>
<td>$15.0</td>
<td>$15.7</td>
<td>$160.00</td>
<td>$33.0K</td>
<td align="right">335</td>
<td align="right">231</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>Having examined the options trading patterns of Biogen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Biogen</h3>
<ul>
<li>Trading volume stands at 594,099, with BIIB's price up by 0.47%, positioned at $159.45.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Biogen</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $229.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup has revised its rating downward to Neutral, adjusting the price target to $190.<br />
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $270.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Biogen, which currently sits at a price target of $210.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Biogen with a target price of $207.<br />
&#x2A; An analyst from Needham has revised its rating downward to Hold, adjusting the price target to $270. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BIIB

Smart Money Is Betting Big In BIIB Options

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Vertiv Hldgs</strong>.</p>
<p>Looking at options history for Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) we detected 28 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 8 are puts, for a total amount of $282,916 and 20, calls, for a total amount of $2,383,168.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $185.0 for Vertiv Hldgs over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Vertiv Hldgs's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertiv Hldgs's whale activity within a strike price range from $70.0 to $185.0 in the last 30 days. </p>
<h3>Vertiv Hldgs Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732646816_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$13.6</td>
<td>$12.2</td>
<td>$13.2</td>
<td>$185.00</td>
<td>$528.0K</td>
<td>153</td>
<td align="right">400</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$33.0</td>
<td>$32.8</td>
<td>$33.0</td>
<td>$100.00</td>
<td>$297.0K</td>
<td>2.1K</td>
<td align="right">93</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.9</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$150.00</td>
<td>$269.2K</td>
<td>1.6K</td>
<td align="right">120</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.9</td>
<td>$25.2</td>
<td>$25.4</td>
<td>$150.00</td>
<td>$218.4K</td>
<td>1.6K</td>
<td align="right">206</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$43.1</td>
<td>$42.3</td>
<td>$42.51</td>
<td>$90.00</td>
<td>$211.6K</td>
<td>1.0K</td>
<td align="right">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertiv Hldgs</h3>
<p>Vertiv Holdings Co brings together hardware, software, analytics and ongoing services to ensure its customers vital applications run continuously, perform optimally and grow with their business needs. The company solves the important challenges faced by data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Its services include critical power, thermal management, racks and enclosures, monitoring and management, and other services. Its three business segments include the Americas, Asia Pacific; and Europe, Middle East &amp; Africa.</p>
<p>Following our analysis of the options activities associated with Vertiv Hldgs, we pivot to a closer look at the company's own performance.</p>
<h3>Vertiv Hldgs's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,472,973, the VRT's price is up by 1.08%, now at $133.46. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 85 days.</li>
</ul>
<h3>What Analysts Are Saying About Vertiv Hldgs</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $140.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from UBS lowers its rating to Buy with a new price target of $155.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Vertiv Hldgs with a target price of $145.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Vertiv Hldgs, maintaining a target price of $131.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Vertiv Hldgs, targeting a price of $141.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Vertiv Hldgs, maintaining a target price of $132. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vertiv Hldgs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


What the Options Market Tells Us About Vertiv Hldgs

<p><strong>Goldman Sachs</strong> analyst Kate McShane reiterated the Buy rating on <strong>Bath &amp; Body Works, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>),<a target="_blank" href="https://www.benzinga.com/quote/BBWI/analyst-ratings" rel="noreferrer noopener"> with a price forecast of $52.</a></p>
<p>The company&#8217;s third-quarter adjusted earnings per share of 49 cents <a target="_blank" href="https://www.benzinga.com/24/11/42163526/bath-body-works-delivers-growth-amid-challenges-beats-q3-targets-and-lifts-2024-projections" rel="noreferrer noopener">beat the analyst consensus of 47 cents.</a> Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, came above the street view of $1.579 billion.</p>
<p>The gross margin was 43.5%, down 20 bps YoY, and the operating margin was 13.5% compared to 14.2% YoY.</p>
<p>The analyst projects the company well-positioned to offer affordable luxury products. McShane sees customers spending more in 2025.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns" rel="noreferrer noopener">Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs &#8216;As A Weapon&#8217;</a></strong></p>
<p>The company has many growth initiatives, such as new products, collaborations, and personalized marketing.</p>
<p>The analyst highlights the company&#8217;s sales forecast might be too low due to strong business momentum and increased spending in the fourth quarter.</p>
<p>The company is now guiding an adjusted EPS of $3.15 &#8211; 3.28 (vs. $3.06 &#8211; 3.26 prior). The company raised fiscal 2024&nbsp;guidance&nbsp;and expects net sales to decline&nbsp;2.5%&nbsp;–&nbsp;1.7%&nbsp;(prior view: decline of&nbsp;4%&nbsp;–&nbsp;2%), including a 100-basis-point headwind from the 53rd week in 2023.&nbsp;</p>
<p>In the analyst&#8217;s view, the company&#8217;s top line guidance could prove conservative given the momentum of the business.</p>
<p>Looking to the remainder of FY24, the analyst sees less upside to gross margins as the company continues to focus on value, which should help drive the top line more effectively.</p>
<p>McShane raised the FY24 net sales growth estimate to -1.7% (from -2.5%), slightly increased the gross margin estimate to 44.1% (from 44.0%), and revised the FY24 EPS estimate to $3.23 from $3.11.</p>
<p>Additionally, the analyst increased the FY25 and FY26 EPS estimates by 4.9% and 1.4%, respectively, to $3.67 and $4.03.</p>
<p><strong>Price Action:</strong> BBWI shares are trading lower by 0.72% to $35.52 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says" target="_blank" rel="noreferrer noopener">&#8216;It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></strong></li>
</ul>
<p><em>Photo via <a href="https://commons.wikimedia.org/wiki/File:VINTAGE_Bath_%26_Body_Works;_Shenango_Valley_Mall;_Hermitage_PA.jpg">Wikimedia Commons</a></em>.</p>


Analyst Color

Equities

News

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

BBWI

Bath & Body Works' Sales Forecast Too Modest? Goldman Sachs Cites Momentum And Consumer Trends

<p><strong>H World Group Limited</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) shares are&nbsp;trading lower on Tuesday after the company&nbsp;reported worse-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42184458/h-world-group-limited-reports-third-quarter-of-2024-unaudited-financial-results" rel="noreferrer noopener">than-expected third-quarter results</a>.</p>
<p>Adjusted earnings per ADS of 61 cents,&nbsp;missing the analyst consensus of 69 cents.</p>
<p>Quarterly sales of&nbsp;$918 million&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the street view of&nbsp;$933.86 million.</a></p>
<p>Revenue rose by&nbsp;2.4%&nbsp;year-over-year, within the previously forecasted guidance of&nbsp;an increase of 2% to 5%<em>&nbsp;</em>for the&nbsp;third quarter&nbsp;of 2024.</p>
<p>Revenue from the Legacy-Huazhu segment grew by&nbsp;1%&nbsp;year-over-year, aligning with the previously announced 1%&nbsp;to&nbsp;4%&nbsp;guidance, while revenue from the Legacy-DH segment saw an&nbsp;8.9%&nbsp;year-over-year increase.</p>
<p>As of Sept. 30, 10,845&nbsp;hotels and over one million hotel rooms were in operation.</p>
<p>In the&nbsp;third quarter, revenue from leased and owned hotels&nbsp;was&nbsp;$526&nbsp;million, representing a decline of&nbsp;4.8%&nbsp;year-over-year and a&nbsp;0.2%&nbsp;quarter-over-quarter increase.&nbsp;</p>
<p>Revenue from manachised and franchised hotels&nbsp;in the quarter was&nbsp;$371&nbsp;million, representing a&nbsp;14.7%&nbsp;year-over-year growth.</p>
<p>Hotel turnover increased&nbsp;10.7%&nbsp;year-over-year in the&nbsp;third quarter. Adjusted EBITDA reached&nbsp;$300&nbsp;million&nbsp;in the quarter.</p>
<p>As of Sept. 30, 2024, the company had cash and cash equivalents of $1 billion and restricted cash of $98 million.</p>
<p><strong>Outlook:&nbsp;</strong>For the&nbsp;fourth quarter, the company anticipates revenue growth of&nbsp;1%–5%<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">, excluding the DH segment.</a></p>
<p>&#8220;This quarter, Legacy-Huazhu&#8217;s blended RevPAR declined by 8% year-over-year primarily due to a high ADR base in the same period last year and unfavorable weather. Our occupancy rate remained solid at 85% despite our ongoing rapid hotel network expansion,&#8221; <strong>Jin Hui</strong>, CEO of H World said.</p>
<p>&#8221;We aim to expand our presence across all regions and continue penetrating into lower-tier cities in China, thereby reaching more of China&#8217;s hotel market with our high-quality hotel products with excellent services,&#8221; Jin noted.</p>
<p>&#8220;Regarding our business outside China, our Legacy-DH business recorded a 3.7% year-over-year blended RevPAR increase in the third quarter of 2024. We continued focusing on cost reduction in our European business, while at the same time seeking growth opportunities in the Asia-Pacific (APAC) and in the Middle East areas,&#8221; he added.</p>
<p><strong>HTHT</strong> <strong>Price Action: </strong>H World Group shares are down 5.89% at $33.10 at publication Tuesday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/42194170" target="_blank" rel="noreferrer noopener">Nokia, du Complete Transport Network Slicing Trial In UAE: Details</a></strong></li>
</ul>


Earnings

Large Cap

Guidance

Travel

HTHT

H World Group Sees Declining Revenue From Leased Hotels, Adjusted EPS Misses Estimate

WIIM

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon Solar Technologies shares are trading lower after the company announced a restructuring of its business portfolio and geographic market to focus exclusively on the US. The stock earlier rose and has since reversed.

<p><a href="https://www.marijuanamoment.net/democratic-congressional-lawmakers-push-biden-to-issue-marijuana-executive-order-before-trump-takes-office/" title="https://www.marijuanamoment.net/democratic-congressional-lawmakers-push-biden-to-issue-marijuana-executive-order-before-trump-takes-office/">https://www.marijuanamoment.net/democratic-congressional-lawmakers-push-biden-to-issue-marijuana-executive-order-before-trump-takes-office/</a></p>


Cannabis

AKAN

CRON

GRWG

IMCC

LFLY

MSOS

SNDL

TLRY

'Democratic Congressional Lawmakers Push Biden To Issue Marijuana Executive Order Before Trump Takes Office' - Marijuana Moment

<p>Deep-pocketed investors have adopted a bearish approach towards KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in KLAC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for KLA. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 26% leaning bullish and 60% bearish. Among these notable options, 10 are puts, totaling $948,774, and 5 are calls, amounting to $258,150.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $350.0 to $890.0 for KLA during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of KLA stands at 142.18, with a total volume reaching 965.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in KLA, situated within the strike price corridor from $350.0 to $890.0, throughout the last 30 days.</p>
<h3>KLA 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732645857_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$76.8</td>
<td>$71.4</td>
<td>$75.0</td>
<td>$700.00</td>
<td>$225.0K</td>
<td align="right">405</td>
<td align="right">30</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$74.6</td>
<td>$69.7</td>
<td>$72.0</td>
<td>$690.00</td>
<td>$216.0K</td>
<td align="right">0</td>
<td align="right">30</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.0</td>
<td>$10.4</td>
<td>$11.0</td>
<td>$610.00</td>
<td>$121.0K</td>
<td align="right">349</td>
<td align="right">315</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$266.9</td>
<td>$259.9</td>
<td>$263.5</td>
<td>$890.00</td>
<td>$105.4K</td>
<td align="right">4</td>
<td align="right">4</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$50.7</td>
<td>$48.4</td>
<td>$48.7</td>
<td>$600.00</td>
<td>$97.4K</td>
<td align="right">96</td>
<td align="right">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About KLA</h3>
<p>KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.</p>
<p>Following our analysis of the options activities associated with KLA, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of KLA</h3>
<ul>
<li>With a volume of 397,514, the price of KLAC is down -2.84% at $626.34. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 58 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for KLA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


KLAC

A Closer Look at KLA's Options Market Dynamics

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Morgan Stanley</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 30 uncommon options trades for Morgan Stanley.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 53% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $502,580, and 26 are calls, for a total amount of $1,348,095.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $97.5 to $200.0 for Morgan Stanley over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Morgan Stanley options trades today is 3122.64 with a total volume of 12,107.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Morgan Stanley's big money trades within a strike price range of $97.5 to $200.0 over the last 30 days.</p>
<h3>Morgan Stanley 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732645852_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.2</td>
<td>$10.35</td>
<td>$11.2</td>
<td>$140.00</td>
<td>$358.4K</td>
<td>627</td>
<td align="right">320</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$25.3</td>
<td>$23.45</td>
<td>$24.6</td>
<td>$125.00</td>
<td>$172.2K</td>
<td>132</td>
<td align="right">70</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$21.75</td>
<td>$21.25</td>
<td>$21.25</td>
<td>$130.00</td>
<td>$159.3K</td>
<td>204</td>
<td align="right">77</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$23.4</td>
<td>$23.1</td>
<td>$23.1</td>
<td>$110.00</td>
<td>$115.5K</td>
<td>715</td>
<td align="right">58</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.45</td>
<td>$8.15</td>
<td>$8.36</td>
<td>$150.00</td>
<td>$83.6K</td>
<td>1.4K</td>
<td align="right">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Morgan Stanley</h3>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.</p>
<h3>Present Market Standing of Morgan Stanley</h3>
<ul>
<li>Trading volume stands at 4,603,902, with MS's price down by -2.15%, positioned at $130.78.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 51 days.</li>
</ul>
<h3>Expert Opinions on Morgan Stanley</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $136.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from HSBC downgraded its rating to Hold, setting a price target of $131.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Morgan Stanley, targeting a price of $135.<br />
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $142. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Morgan Stanley options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Looking At Morgan Stanley's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>General Motors</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 66 uncommon options trades for General Motors.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 39%, bearish.</p>
<p>Out of all of the special options we uncovered, 40 are puts, for a total amount of $2,717,669, and 26 are calls, for a total amount of $2,043,567.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $80.0 for General Motors over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for General Motors's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of General Motors's whale trades within a strike price range from $35.0 to $80.0 in the last 30 days. </p>
<h3>General Motors Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732645847_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.25</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$62.50</td>
<td>$600.0K</td>
<td>106</td>
<td>1.0K</td>
</tr>
<tr>
<td>GM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$57.50</td>
<td>$290.8K</td>
<td>2.9K</td>
<td>607</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$4.45</td>
<td>$4.2</td>
<td>$4.45</td>
<td>$80.00</td>
<td>$268.3K</td>
<td>2.3K</td>
<td>1.3K</td>
</tr>
<tr>
<td>GM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.71</td>
<td>$2.63</td>
<td>$2.63</td>
<td>$58.00</td>
<td>$131.6K</td>
<td>1.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$55.00</td>
<td>$121.7K</td>
<td>8.8K</td>
<td>3.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About General Motors</h3>
<p>General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company regained its us market share leader crown in 2022, after losing it to Toyota due to the chip shortage in 2021. 2023's share was 16.5%. GM's Cruise autonomous vehicle arm has previously done driverless geofenced AV robotaxi services in San Francisco and other cities but stopped in late 2023 after an accident. It restarted service in 2024 but not in California. GM owns over 80% of Cruise. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.</p>
<h3>Present Market Standing of General Motors</h3>
<ul>
<li>With a volume of 15,241,874, the price of GM is down -8.07% at $55.34. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 63 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for General Motors, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


General Motors Unusual Options Activity

<p>The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's <a href="https://www.benzinga.com/topic/interest-rates">November meeting minutes</a>. </p>
<p>Reports are expected to provide fresh critical insights into the central bank's outlook for interest rates. Fed futures currently assign a 59% probability of a 25-basis-point rate cut in December. The remaining odds suggest the Fed may hold rates steady in the 4.5%-4.75% range, as per CME FedWatch.</p>
<p>Fed futures are currently assigning a 59% chance to a 25-basis-point Fed rate cut in December, while remaining odds point to the option of holding rates steady at 4.5%-4.75%, as per CME FedWatch. </p>
<h3 class="wp-block-heading">25% Tariffs On All Imports</h3>
<p>In a relatively quiet trading session, both Mexican and Canadian assets saw a surge in volatility after President-elect <strong>Donald</strong> <strong>Trump</strong> pledged to <a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">raise tariffs to 25% on all imports from Mexico and Canada</a>, citing efforts to combat drug trafficking and illegal immigration.</p>
<p>The Mexican peso dropped 2.5%, falling to 22.80 per U.S. dollar, a level of weakness not seen since August 2022. The <strong>iShares MSCI Mexico ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) also declined sharply, tumbling 2.9%.</p>
<p>President <strong>Claudia Sheinbaum</strong> responded with a retaliatory warning, suggesting Mexico could impose its own tariffs, escalating the risk of economic damage for both nations.</p>
<p>The Canadian dollar fared slightly better, sliding 0.7% but still reaching its lowest level in more than four years.</p>
<p>U.S. Treasury yields ticked higher, reversing some of the sharp declines seen on Monday following President-elect Trump's announcement of Scott Bessent as his pick for Treasury Secretary. The <strong>iShares 20+ Year Treasury Bond ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.5%, cooling off after Monday's 2.6% rally.</p>
<p>Gold traded flat, remaining near $2,010 per ounce. Oil prices fell 0.8% to $68.30 per barrel, as markets monitored developments around the ceasefire deal between Israel and Hezbollah as the Israeli Security Cabinet meets for the official approval.</p>
<p><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose slightly by 0.7%, after logging its worst single-day performance in more than four months on Monday. </p>
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<p><figure class="wp-block-table is-style-stripes"><br />
<table>
<tbody>
<tr>
<td><strong>Major Indices</strong></td>
<td><strong>Price</strong></td>
<td><strong>% (1-day)</strong></td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,013.26</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,891.08</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,656.98</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,426.91</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<p><figcaption class="wp-element-caption"><em>Updated at 12:52 p.m. ET</em></figcaption></p></figure></p>
<p><strong>According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:</strong></p>
<ul>
<li>The&nbsp;<strong>SPDR S&amp;P 500 ETF Trust</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged 0.4% higher to $596.83, eyeing the seventh straight session of gains.</li>
<li>The&nbsp;<strong>SPDR Dow Jones Industrial Average&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $447.10.</li>
<li>The tech-heavy&nbsp;<strong>Invesco QQQ Trust Series</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.5% up to $508.98.</li>
<li>The&nbsp;<strong>iShares Russell 2000 ETF</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.4% to $241.28.</li>
<li>The&nbsp;<strong>Utilities Sector Select Sector SPDR Fund</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1%. The&nbsp;<strong>Materials Select Sector SPDR Fund</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 0.9%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Shares of automakers fell after President-elect <strong>Donald Trump</strong> threatened tariffs on goods <a href="https://www.benzinga.com/news/global/24/11/42196251/general-motors-stellantis-lead-automaker-stock-declines-as-trump-proposes-aggressive-tariffs-on-mexico-canada">imported from Canada and Mexico.</a> <strong>Ford Motor Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), <strong>General Motors Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and <strong>Stellantis N.V.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) were down 2.3%, 8.4% and 5.3%, respectively. For GM this may potentially mark the worst day since August 2021. </li>
<li><strong>Eli Lilly &amp; Co. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) rose 5.4% while <strong>Amgen Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) tumbled over 8%, after the latter saw weight-loss drug results coming in below analyst expectations.  </li>
<li><strong>Zoom Video Communications Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) fell over 7% in reaction to quarterly earnings. </li>
<li>Other stocks reacting to quarterly results included <strong>Semtech Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>), up 18%, <strong>Analog Devices Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>), down 3%, <strong>Agilent Technologies Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), down 1.8%, <strong>Woodward Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>), up 6%, <strong>Best Buy Co. Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), down 7%, <strong>Dicks Sporting Goods Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), down 0.2%, <strong>VinFast Auto Ltd. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>), up 1%. </li>
</ul>
<p><strong>Check Out:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/psychology/24/11/42196027/amazon-dominates-holiday-shopping-as-black-friday-spending-soars-goldman-sachs">Amazon Dominates Holiday Shopping As Black Friday Spending Soars: Goldman Sachs</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Mid Cap

Broad U.S. Equity ETFs

Emerging Markets

Emerging Market ETFs

Commodities

Politics

Global

Econ #s

Federal Reserve

ETFs

$BTC

AMGN

SPDR Dow Jones Industrial Average ETF Trust

SMTC

STLA

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?

<p><a href="https://www.cnn.com/world/live-news/israel-hezbollah-ceasefire-deal-gaza-war-11-26-24-intl-hnk/index.html" title="https://www.cnn.com/world/live-news/israel-hezbollah-ceasefire-deal-gaza-war-11-26-24-intl-hnk/index.html">https://www.cnn.com/world/live-news/israel-hezbollah-ceasefire-deal-gaza-war-11-26-24-intl-hnk/index.html</a></p>


Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Israeli PM Netanyahu Says We Will Return All Citizens In North To Their Homes; We Are Committed To Returning Remaining Hostages From Gaza; Syria's Assad Is Playing With Fire; We Have Set Hezbollah Back Decades; If Hezbollah Breaks The Deal We Will Strike At Them; Will Bring The Full Cabinet An Outline For Ceasefire With Lebanon

<p>The U.S. Department of Justice's trial on proposed penalties against Alphabet's Google over its dominance in the online search market will not be delayed to accommodate any changes Trump administration officials wish to make, the judge overseeing the case said on Tuesday.</p>
<p>U.S. District Judge Amit Mehta said he would not move the trial, scheduled for April, for that purpose.</p>
<p>&nbsp;</p>
<p>"If there is going to be a re-evaluation of the remedies that are being requested, it needs to be done quickly," the judge said.</p>
<p>Prosecutors have asked the judge to order Google to sell its Chrome browser, share data and search results with rivals and take other measures - including possibly selling the Android mobile operating system.</p>
<p>Google has called the proposals staggering, and said they would harm American competitiveness.</p>


Legal

"U.S. Judge In Google Search Case Says If Trump Administration Wants To Make A 'Reevaluation Of The Remedies' Then It Needs To Do So Quickly; Says April Trial In DOJ's Google Search Case Will Not Be Rescheduled For DOJ To Revise Proposals" - Reuters News

<p><strong>ASP Isotopes Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) shares are trading lower on Tuesday. The stock initially moved higher after the company announced it completed construction and started commissioning its Silicon-28 enrichment facility, but reversed course after a short seller issued a bearish report on the stock. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/24/11/g42187863/asp-isotopes-inc-completes-construction-and-starts-the-commissioning-of-silicon-28-enrichment-faci">you need to know</a>.</p>
<p><strong>What Happened:</strong> Short Seller Fuzzy Panda Research issued a bearish report on ASP Isotopes on Tuesday claiming the company is using &#8220;old, disregarded laser enrichment technology to masquerade as a new, cutting-edge Uranium enrichment company.&#8221;</p>
<p>Fuzzy Panda claimed that it uncovered multiple stock promoters who were paid to promote ASP Isotopes. The short seller also claimed that family members of <strong>Barry Honig</strong> and<strong> John Stetson</strong>, who are currently banned from penny stocks trading, have stakes in ASP Isotopes. </p>
<p>A spokesperson for ASP Isotopes told Benzinga the Fuzzy Panda report includes inaccurate claims. </p>
<p>&#8220;We are aware of the report by a known activist short seller who stands to realize gains by a company's shares declining in value,&#8221; the ASP Isotopes spokesperson said. </p>
<p>&#8220;The report includes inaccurate claims and innuendo in an attempt to mislead investors. As a public company traded on Nasdaq, we direct investors to our public filings made with the SEC.&#8221;</p>
<p>Fuzzy Panda noted in the report that <strong>Cameco</strong> looked at ASP Isotope&#8217;s technology but decided to pass on investing. The short seller also noted that the company&#8217;s recent memorandum of understanding with <strong>Bill Gates</strong>-backed <a href="https://www.benzinga.com/news/24/10/41624818/asp-isotopes-stock-is-soaring-wednesday-whats-going-on" target="_blank" rel="noreferrer noopener">TerraPower</a>&nbsp;is non-binding and did not cost TerraPower anything to enter into.</p>
<p>ASP Isotopes shares raced higher at the end of October after the company signed a deal with&nbsp;TerraPower&nbsp;related to&nbsp;the construction of a uranium enrichment facility capable of producing&nbsp;High Assay Low-Enriched Uranium (HALEU). ASP Isotopes said last week that it has received interest from potential customers who collectively require over $37 billion of HALEU between now and 2037.</p>
<p>The short seller went on to cast doubt on the company&#8217;s ability to obtain licenses and called the company&#8217;s cost estimate forecasts &#8220;delusional.&#8221; </p>
<p>&#8220;Management has issued false promises and promised milestones since the beginning,&#8221; the short seller said.</p>
<p><strong>Check This Out: <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/42190391/dell-93-rally-hits-q3-crossroads-whats-next-for-the-stock">Dell&#8217;s 93% Rally Hits Q3 Crossroads – What&#8217;s Next For The Stock?</a></strong></p>
<p><strong>What Else:</strong> ASP Isotopes shares actually started the day higher after the company announced that construction of its Silicon-28 enrichment facility in South Africa was completed. The company began the commissioning phase on Tuesday and is targeting supplying commercial quantities of Silicon-28 during the first half of 2025.</p>
<p>Silicon-28 is an isotope that is believed to enable quantum computing and is also likely to improve the performance of next-gen AI chips. Highly enriched Silicon-28 is expected to be required by manufacturers of next-gen semiconductors, the company said. </p>
<p>&#8220;To create faster, smaller next-generation semiconductors, the world is likely going to require materials that are currently not available in commercial quantities,&#8221; said <strong>Paul Mann</strong>, chairman and CEO of ASP Isotopes. </p>
<p>&#8220;ASP Isotopes is currently working on many isotopically pure elements that we believe will help semiconductor companies create the chips that the world will require in the future to enable technologies such as quantum computing and artificial intelligence.&#8221;</p>
<p>ASP Isotopes said it already signed two supply agreements with U.S.-based customers for highly enriched Silicon-28. One of the customers is a semiconductor company and the other is an industrial gas company. ASP noted that it&#8217;s currently in discussions with multiple other potential customers and expects to sign more agreements within the next six months. </p>
<p><strong>ASPI Price Action:</strong> <a href="http://benzinga.com/quote/aspi" target="_blank" rel="noreferrer noopener">ASP Isotopes shares</a> were down 23.3% at $5.86 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>


Short Sellers

ASPI

What's Going On With ASP Isotopes Stock Tuesday?

<p><em>Editor&#8217;s note: The headline of this story was updated to correct an error related to the reported day of the week.</em></p>
<p>On Monday, the Centers for Medicare &amp; Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.</p>
<p>Included was a final decision related to CMS pricing for <strong>Exact Sciences Corp&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus, a second-generation test that received FDA <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">approval in October</a>.</p>
<p>William Blair writes that the <a target="_blank" href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings" rel="noreferrer noopener">determinations</a> effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a></strong></p>
<p>The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.</p>
<p>The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).</p>
<p>This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.</p>
<p>The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.</p>
<p>William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a></p>
<p>The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.</p>
<p>From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair&#8217;s estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.</p>
<p>Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42177702/exact-sciences-advances-breast-cancer-care-with-the-oncotype-dx-test-and-genomic-profiling-researc" rel="noreferrer noopener">scheduled next month</a>.</p>
<p><strong>Price Action:</strong> EXAS stock is up 7.60% at $59.33 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a></strong></li>
</ul>
<p><em>Illustration of Phrama lab worker created with MidJourney.</em></p>


Health Care

General

EXAS

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

JPMorgan Expects $5B-$15B In Outflows From Emerging Market Dedicated Bond Funds In 2025; Expects Growth To Slow In Emerging Markets To 3.4% In 2025, From 4.1% In 2024; Sees $169B Of EM Sovereign Hard Currency Gross Issuance In 2025, Marginally Less Than 2024

Government

'Trump's Plan To Impose 25% Tariffs On Canadian And Mexican Imports Does Not Exempt Crude Oil - Sources'

<p><a href="https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/" title="https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/">https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/</a></p>


'Israel Security Cabinet Approves Ceasefire Deal With Lebanon - TV' - Reuters

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Intuitive Surgical</strong>.</p>
<p>Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 9% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $77,900 and 9, calls, for a total amount of $448,950.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $560.0 for Intuitive Surgical, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 157.75 with a total volume of 182.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $240.0 to $560.0 over the last 30 days.</p>
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732644997_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$19.6</td>
<td>$19.7</td>
<td>$550.00</td>
<td>$78.8K</td>
<td align="right">575</td>
<td align="right">54</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$65.0</td>
<td>$60.7</td>
<td>$65.0</td>
<td>$520.00</td>
<td>$65.0K</td>
<td align="right">173</td>
<td align="right">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$64.9</td>
<td>$61.4</td>
<td>$63.0</td>
<td>$520.00</td>
<td>$63.0K</td>
<td align="right">173</td>
<td align="right">20</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$305.0</td>
<td>$300.7</td>
<td>$302.7</td>
<td>$240.00</td>
<td>$60.5K</td>
<td align="right">52</td>
<td align="right">2</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$28.8</td>
<td>$27.6</td>
<td>$28.8</td>
<td>$560.00</td>
<td>$57.6K</td>
<td align="right">140</td>
<td align="right">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a trading volume of 478,667, the price of ISRG is up by 0.66%, reaching $540.1.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ISRG

Unpacking the Latest Options Trading Trends in Intuitive Surgical

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Microchip Technology</strong>.</p>
<p>Looking at options history for Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $647,449 and 3, calls, for a total amount of $215,668.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $47.5 to $87.5 for Microchip Technology during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Microchip Technology stands at 373.38, with a total volume reaching 5,381.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Microchip Technology, situated within the strike price corridor from $47.5 to $87.5, throughout the last 30 days.</p>
<h3>Microchip Technology Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732644993_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$70.00</td>
<td>$430.3K</td>
<td>489</td>
<td>1.4K</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.9</td>
<td>$70.00</td>
<td>$98.0K</td>
<td>584</td>
<td>212</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.3</td>
<td>$2.2</td>
<td>$2.18</td>
<td>$77.50</td>
<td>$76.7K</td>
<td>140</td>
<td>751</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.05</td>
<td>$2.0</td>
<td>$2.05</td>
<td>$67.50</td>
<td>$49.6K</td>
<td>1.1K</td>
<td>435</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.8</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$70.00</td>
<td>$41.0K</td>
<td>298</td>
<td>314</td>
</tr>
</tbody>
</table>
</p>
<h3>About Microchip Technology</h3>
<p>Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.</p>
<p>In light of the recent options history for Microchip Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Microchip Technology</h3>
<ul>
<li>Trading volume stands at 3,162,874, with MCHP's price down by -1.88%, positioned at $68.54.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 65 days.</li>
</ul>
<h3>Professional Analyst Ratings for Microchip Technology</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $88.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Susquehanna persists with their Positive rating on Microchip Technology, maintaining a target price of $90.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Microchip Technology, targeting a price of $82.<br />
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Microchip Technology with a target price of $90.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Microchip Technology with a target price of $85.<br />
&#x2A; An analyst from Evercore ISI Group downgraded its action to Outperform with a price target of $95. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Comments

Iris Acquisition

Iris Acquisition (IRAAU) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga